Agenus Inc (AGEN)
15.69
+0.58
(+3.84%)
USD |
NASDAQ |
May 31, 16:00
15.66
-0.03
(-0.19%)
After-Hours: 20:00
Agenus Enterprise Value: 301.30M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 301.30M |
| May 30, 2024 | 289.13M |
| May 29, 2024 | 287.45M |
| May 28, 2024 | 292.07M |
| May 24, 2024 | 257.84M |
| May 23, 2024 | 231.17M |
| May 22, 2024 | 221.93M |
| May 21, 2024 | 205.34M |
| May 20, 2024 | 196.52M |
| May 17, 2024 | 199.88M |
| May 16, 2024 | 192.32M |
| May 15, 2024 | 198.20M |
| May 14, 2024 | 196.52M |
| May 13, 2024 | 204.71M |
| May 10, 2024 | 192.11M |
| May 09, 2024 | 217.94M |
| May 08, 2024 | 212.69M |
| May 07, 2024 | 224.03M |
| May 06, 2024 | 243.77M |
| May 03, 2024 | 246.29M |
| May 02, 2024 | 234.68M |
| May 01, 2024 | 250.21M |
| April 30, 2024 | 226.28M |
| April 29, 2024 | 239.72M |
| April 26, 2024 | 217.25M |
| Date | Value |
|---|---|
| April 25, 2024 | 146.08M |
| April 24, 2024 | 127.61M |
| April 23, 2024 | 107.45M |
| April 22, 2024 | 92.96M |
| April 19, 2024 | 83.31M |
| April 18, 2024 | 76.17M |
| April 17, 2024 | 85.20M |
| April 16, 2024 | 103.79M |
| April 15, 2024 | 107.98M |
| April 12, 2024 | 142.54M |
| April 11, 2024 | 158.04M |
| April 10, 2024 | 159.14M |
| April 09, 2024 | 176.10M |
| April 08, 2024 | 167.28M |
| April 05, 2024 | 183.32M |
| April 04, 2024 | 184.24M |
| April 03, 2024 | 194.41M |
| April 02, 2024 | 186.81M |
| April 01, 2024 | 218.51M |
| March 31, 2024 | 215.36M |
| March 28, 2024 | 191.73M |
| March 27, 2024 | 181.84M |
| March 26, 2024 | 173.46M |
| March 25, 2024 | 182.68M |
| March 22, 2024 | 177.53M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
76.17M
Minimum
Apr 18 2024
1.453B
Maximum
Aug 30 2021
484.16M
Average
447.72M
Median
Jan 07 2020
Enterprise Value Benchmarks
| Ligand Pharmaceuticals Inc | 1.220B |
| Protalix BioTherapeutics Inc | 54.78M |
| InfuSystems Holdings Inc | 181.16M |
| PAVmed Inc | 85.05M |
| Allogene Therapeutics Inc | 135.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.89M |
| Revenue (Quarterly) | 28.00M |
| Total Expenses (Quarterly) | 60.89M |
| EPS Diluted (Quarterly) | -60.80 |
| Gross Profit Margin (Quarterly) | -57.23% |
| Profit Margin (Quarterly) | -221.0% |
| Earnings Yield | -448.7% |
| Normalized Earnings Yield | -448.74 |